

5<sup>th</sup> November, 2025

**BSE Limited**  
P.J. Towers, Dalal Street, Fort,  
Mumbai- 400 001  
BSE scrip code: 543635

**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051  
NSE symbol: PPLPHARMA

**Sub: Press Release and Investor Presentation – Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended 30<sup>th</sup> September, 2025**

Dear Sir / Madam,

Further to our intimation made earlier with regard to Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended 30<sup>th</sup> September, 2025 ('Financial Results'), please find enclosed herewith the Press Release and the Investor Presentation on the Financial Results.

The above information is also available on the website of the Company at <https://www.piramalpharma.com/>.

You are requested to kindly take the above information on record.

Yours truly,  
For **Piramal Pharma Limited**

**Tanya Sanish**  
**Company Secretary**  
Encl.: a/a

PRESS RELEASE

## Piramal Pharma Limited Announces Results for Q2 and H1 FY26

**Mumbai, India | November 05, 2025:** Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Second Quarter (Q2) and Half Year (H1) ended 30<sup>th</sup> September 2025.

### Consolidated Financial Highlights

(in ₹ Crores or as stated)

Particulars	Q2FY26	Q2FY25	YoY Growth	H1FY26	H1FY25	YoY Growth
<b>Revenue from Operations</b>	<b>2,044</b>	<b>2,242</b>	<b>(9)%</b>	<b>3,977</b>	<b>4,193</b>	<b>(5)%</b>
CDMO	1,044	1,324	(21)%	2,041	2,381	(14)%
CHG	644	643	0%	1,281	1,274	1%
ICH	319	277	15%	621	541	15%
<b>EBITDA</b>	<b>224</b>	<b>403</b>	<b>(44)%</b>	<b>389</b>	<b>627</b>	<b>(38)%</b>
<b>EBITDA Margin</b>	<b>11%</b>	<b>18%</b>		<b>10%</b>	<b>15%</b>	
<b>PAT</b>	<b>(99)</b>	<b>23</b>	<b>NM</b>	<b>(181)</b>	<b>(66)</b>	<b>NM</b>

### Key Highlights for Q2 and H1 FY26

- **Revenue from Operations** for the quarter and half-year FY26 stood at ₹ 2,044 crores and ₹ 3,977 crores respectively. The YoY growth was impacted due to inventory destocking by the customer in one large CDMO order.
- **EBITDA margin** for the quarter and half-year FY26 were 11% and 10% respectively. Despite lower revenues in H1FY26, its impact on EBITDA was partly offset by our efforts towards cost optimization and operational excellence.
- **Net-Debt** at the end of H1FY26 reduced by ₹ 228 crores (vs. FY25) to ₹ 3,971 crores supported by tight control over working capital and capex investments, maintaining our net debt to EBITDA ratio below 3x.
- **Sustainability**– Released our 4<sup>th</sup> Annual Sustainability Report for the FY25, under the theme ‘Innovating Responsibly. Growing Sustainably’, which has also been assured by DNV Business Assurance India Pvt Ltd. The report outlines measurable progress and strengthened commitments under our four strategic pillars.

**Nandini Piramal, Chairperson, Piramal Pharma Limited** said, “YoY growth in the CDMO Business was primarily impacted by inventory destocking in one large on-patent commercial product. Inconsistent recovery in US biopharma funding along with uncertainties on global trade policies led to adverse impact on order inflows and customer decision making during H1FY26. However, in the months of September and October 2025, we have seen a significant pick up in biopharma funding, which if sustains, should lend impetus to increased RFPs and orders going forward. Also, we are seeing strong customer interest for onshore offerings which bodes well for the investments we have made in our overseas sites. In our CHG business we further strengthened our leadership position in the US Sevoflurane market, while simultaneously working to obtain regulatory approvals for ex-US markets from our India plant. Our consumer business delivered healthy mid-teen growth, seamlessly collaborating with various stakeholders for smooth transition to new GST rates changes.”

## Key Business Highlights for Q2/H1 FY2026

### Contract Development and Manufacturing Organization (CDMO):

- YoY growth during Q2 and H1 FY26 was primarily impacted by **inventory destocking by the customer** in one large CDMO order for on-patent commercial product.
- Inconsistent recovery in US biopharma funding along with uncertainties on global trade policies led to adverse impact on order inflow and decision making by customers in H1FY26. Although, seeing early signs of improvement with **funding uptick in the months of September and October 2025**.
- Efforts towards **cost optimization and operational excellence** helped partially offset impact on EBITDA.
- **Recently increasing RFPs/RFIs**- especially for our onshore manufacturing facilities and differentiated capabilities like ADC, Sterile fill-finish, and on-patent commercial manufacturing, where we have made significant investments in capabilities and capacities.
- **Good progress in the existing development pipeline** – Entered into a multi-million-dollar joint investment at Sellersville site (US), with NewAmsterdam Pharma for commercial manufacturing capacity for FDC of Obicetrapib and Ezetimibe to meet commercial demand.
- **Best-in-Class Quality Track Record** – Successfully closed 19 regulatory inspections, including 1 USFDA inspection with zero observations in H1FY26. Continue to maintain our 'Zero OAI' status.

### Complex Hospital Generics (CHG):

- **Inhalation Anesthesia (IA)** -
  - o Continue to further strengthen our leadership position in the mature US Sevoflurane market with value market share of 45% in Mar'25 - up from 44% in MAT Mar'24. (Source:- IQVIA)
  - o To drive growth, we are working on obtaining regulatory approvals for Sevoflurane in the ex-US markets from our Digwal plant in India.
- **Intrathecal Therapy** – Sales during the quarter was impacted due to temporary supply challenges. Expect supplies to normalize in H2FY26. Maintained our #1 Rank in intrathecal Baclofen in the US with 75% value market share. (Source:- IQVIA)
- **Injectable Anesthesia and Pain Management** – Initiatives to resolve supply constraints starting to yield results.
- **Differentiated and Specialty Products** - Continue to invest in 505(b)(2)'s, complex generics, differentiated generics, and branded products through in-licensing deals or co-development projects to enable long term growth.

### Piramal Consumer Healthcare (PCH):

- **Power Brands** continue to post strong growth of 20% YoY during Q2FY26, contributing to 51% of total PCH sales. Growth was primarily driven by Little's, Lacto Calamine, CIR, and i-range.
- **New Product Launches** - Added 26 new products and SKUs in H1FY26.
- **Investments in Media and Promotions** - 12% of PCH sales in H1FY26.
- **E-commerce** sales grew at over 40% YoY in Q2 and H1FY26, contributing about 24% to PCH sales. More than 40% of e-commerce sales coming from quick commerce.

## Consolidated Profit and Loss Statement

*(in ₹ Crores or as stated)*

Particulars	Quarterly					Half Yearly		
	Q2FY26	Q2FY25	YoY Change	Q1FY26	QoQ Change	H1FY26	H1FY25	YoY Change
Revenue from Operations	2,044	2,242	(9)%	1,934	6%	3,977	4,193	(5)%
Other Income	66	61	7%	58	12%	124	81	54%
<b>Total Income</b>	<b>2,109</b>	<b>2,303</b>	<b>(8)%</b>	<b>1,992</b>	<b>6%</b>	<b>4,101</b>	<b>4,274</b>	<b>(4)%</b>
Material Cost	703	796	(12)%	694	1%	1,397	1,471	(5)%
Employee Expenses	611	560	9%	619	(1)%	1,230	1,139	8%
Other Expenses	571	544	5%	514	11%	1,085	1,037	5%
<b>EBITDA</b>	<b>224</b>	<b>403</b>	<b>(44)%</b>	<b>165</b>	<b>36%</b>	<b>389</b>	<b>627</b>	<b>(38)%</b>
Interest Expenses	82	108	(23)%	86	(4)%	169	215	(21)%
Depreciation	203	192	6%	197	3%	400	377	6%
Share of Net Profit of Associates	15	17	(14)%	19	(20)%	33	40	(16)%
<b>Profit Before Tax</b>	<b>(46)</b>	<b>120</b>	<b>NM</b>	<b>(100)</b>	<b>NM</b>	<b>(146)</b>	<b>75</b>	<b>NM</b>
Tax	53	98	(46)%	3	1,879%	56	141	(61)%
<b>Net Profit after Tax</b>	<b>(99)</b>	<b>23</b>	<b>NM</b>	<b>(102)</b>	<b>NM</b>	<b>(202)</b>	<b>(66)</b>	<b>NM</b>
Exceptional item <sup>1</sup>	-	-	NM	21	NM	21	-	NM
<b>Net Profit after Tax after Exceptional Item</b>	<b>(99)</b>	<b>23</b>	<b>NM</b>	<b>(82)</b>	<b>NM</b>	<b>(181)</b>	<b>(66)</b>	<b>NM</b>

1. Exceptional items include, one time insolvency proceeds received from a claim filed against a third-party supplier of our complex hospital generics business, with the NCLT in November 2023

## Consolidated Balance Sheet

*(in ₹ Cr. or as stated)*

Key Balance Sheet Items	As at	
	30-Sep-25	31-Mar-25
<b>Total Equity</b>	<b>8,073</b>	<b>8,125</b>
Net Debt	3,971	4,199
<b>Total</b>	<b>12,045</b>	<b>12,324</b>
<b>Net Fixed Assets</b>	<b>9,394</b>	<b>9,110</b>
Tangible Assets	4,655	4,534
Intangible Assets including goodwill	3,651	3,599
CWIP (including IAUD <sup>2</sup> )	1,088	977
Net Working Capital	2,201	2,798
Other Assets <sup>3</sup>	450	416
<b>Total Assets</b>	<b>12,045</b>	<b>12,324</b>

2. IAUD – Intangible Assets Under Development; 3. Other Assets include Investments and Deferred Tax Assets (Net)

## Q2 and H1 FY26 Earnings Conference Call

Piramal Pharma Limited will be hosting a conference call for investors / analysts on **06<sup>th</sup> November 2025 from 9:30 AM to 10:15 AM (IST) to discuss its Q2 and H1 FY26 Results.**

The dial-in details for the call are as under:

Event	Location & Time	Telephone Number
Conference call on 06 <sup>th</sup> November, 2025	India – 09:30 AM IST	+91 22 6280 1461 / +91 22 7115 8320 (Primary Number) 1 800 120 1221 (Toll free number)
	USA – 11:00 AM (Eastern Time – New York)	Toll free number 18667462133
	UK – 04:00 AM (London Time)	Toll free number 08081011573
	Singapore – 12:00 PM (Singapore Time)	Toll free number 8001012045
	Hong Kong – 12:00 PM (Hong Kong Time)	Toll free number 800964448
Express Join with Diamond Pass™	Please use this link for prior registration to reduce wait time at the time of joining the call – <a href="#">Click here</a>	

### About Piramal Pharma Limited:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), offers a portfolio of differentiated products and services through its 17<sup>1</sup> global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

For more information, visit: [Piramal Pharma](#) | [LinkedIn](#)

1. Includes one facility via PPL's minority investment in Yapan Bio.

### For Investor Queries:

Gagan Borana  
Investor Relations & Enterprise Risk Management  
[gagan.borana@piramal.com](mailto:gagan.borana@piramal.com)

Madhusudan Dalmia  
Investor Relations  
[madhusudan.dalmia@piramal.com](mailto:madhusudan.dalmia@piramal.com)

### For Media Queries:

Madiha Vahid  
Lead – Branding & Communications  
[madiha.vahid@piramal.com](mailto:madiha.vahid@piramal.com)

# Q2FY26 Results

November 2025



# Piramal Pharma Limited





# Disclaimer

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation, directly or indirectly, in any manner, or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for any securities of the Company in any jurisdiction, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever.

Except for the historical information contained herein, statements in this Presentation and any subsequent discussions, which include words or phrases such as 'will', 'aim', 'will likely result', 'would', 'believe', 'may', 'expect', 'will continue', 'anticipate', 'estimate', 'intend', 'plan', 'contemplate', 'seek to', 'future', 'objective', 'goal', 'likely', 'project', 'on-course', 'should', 'potential', 'pipeline', 'guidance', 'will pursue' 'trend line' and similar expressions or variations of such expressions may constitute 'forward-looking statements'.

Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements.

These risks and uncertainties include, but are not limited to Company's ability to successfully implement its strategy, the Company's growth and expansion plans, the performance of the Indian economy and of the economies of various international markets, obtain regulatory approvals, provisioning policies, technological changes, investment and business income, income or cash flow projections, the performance of the industry in India and world-wide, exposure to market risks as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially from results expressed in or implied by this Presentation.

Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections. Given these uncertainties and other factors, viewers of this Presentation are cautioned not to place undue reliance on these forward-looking statements. The information in this Presentation does not constitute financial advice (nor investment, tax, accounting or legal advice) and does not take into account an investor's individual investment objectives, including the merits and risks involved in an investment in the Company or its securities, or an investor's financial situation, tax position or particular needs. Past performance information in this Presentation should not be relied upon as an indication of (and is not an indicator of) future performance.

This Presentation is not a prospectus, disclosure document, a statement in lieu of a prospectus, an offering circular, an invitation or an advertisement or an offer document under the Companies Act, 2013, together with the rules and regulations made thereunder, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation, and nothing in this Presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. The Presentation has not been independently verified and any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

The contents of this Presentation are strictly confidential and may not be copied or disseminated, reproduced, re-circulated, published, advertised or redistributed, in whole or in part, to any other person or in any media, website or otherwise in any manner without the Company's written consent.

Note: Figures in previous periods might have been regrouped or restated, wherever necessary to make them comparable to current period. For the ease of presentation, certain financial information herein has been rounded off to one decimal place or two decimal places or whole numbers, as the case may be.

# Diversified Global Pharma and Wellness Company


Built a Company with Portfolio of Differentiated Products and Services, and Commercial Presence in 100+ Countries

## CDMO Business

### Integrated CDMO Company

- **15** - Manufacturing and development sites across US, Europe, Canada, and India
- **140+** - Molecules under development with **30+** molecules in Phase III
- **54%** - Share of Innovation related work
- **49%** revenues from differentiated offerings – ADC, HPAPI, Sterile Injectables, Peptides, On-patent API Development & Manufacturing
- **120+** Integrated projects executed


(In ₹ Crore)



## Complex Hospital Generics Business

### A Critical Care Company


- **One of the leading** Inhalation Anesthesia companies in the world
  - **#1** - Rank in US sevoflurane market with **45%** market share
  - **Vertically integrated** manufacturing
- **#1** - Rank in US Intrathecal Baclofen market with **75%** market share
- Commercial presence in **100+** countries and **6,000+** hospitals



## Consumer Healthcare Business

### Consumer Health & Wellness Company

- **Self-funded** and asset light business model with annual revenue of over ₹ 1,000 Crs
- **25+ Brands** – Diversified portfolio across high growth segments
  - **6** - Power Brands growing at ~20% CAGR
- **Multichannel distribution network**
  - **180k+** - Chemists and cosmetics shops
  - **20+** - Presence on e-commerce platforms






# Key Financial Highlights – Q2/H1 FY2026


## Revenue from Operations

(In ₹ Crore)



## EBITDA & EBITDA Margin


(EBITDA: In ₹ Crore)




## Historically, H2 has Outperformed H1

% of Full Year Revenue

■ H1  
■ H2



% of Full Year EBITDA



*YoY growth in revenue and EBITDA during Q2 and H1 FY26 was primarily impacted by inventory destocking in one large on-patent commercial product by the customer*



# Business Wise Performance

---

## Performance Highlights

### ❖ YoY performance during Q2 and H1 FY26 impacted by:

- **Inventory destocking** in one large on-patent commercial product by the customer.
- **Slower early-stage discovery and development order inflows in H1FY26** due to inconsistent recovery in US biopharma funding along with uncertainties on global trade policies leading to adverse impact on order inflow and customer decision making.

Despite lower revenues in H1FY26, its impact on EBITDA was partly offset by our efforts towards cost optimization and operational excellence.

### ❖ Expect better revenue and EBITDA performance going forward driven by:


- **Significant uptick in biopharma funding** in months of September and October 2025. Sustenance of the funding momentum should lend impetus to early-stage order inflows.
- **Recently increasing RFPs/RFIs trends** for our onshore manufacturing facilities and differentiated capabilities like ADC, Sterile fill-finish, and on-patent commercial manufacturing. We have made timely investments to capitalize on the opportunity.
- **Good inflow of commercial orders**
- **Enhancement in our Business Development team** to adapt to the market dynamics and better engage with our customers.

## Revenue Growth

(In ₹ Crore)

▼ (14)%

▼ (21)%





# Strong Customer Interest for our US Sites

## Steadily Increasing our Footprint in the US



Ongoing expansion in Lexington



Riverview



Sellersville

Initiated **US\$ 90 Mn investment** to expand **Lexington** and **Riverview** facilities, part of our **ADCelerate** programme :-

- **Lexington:-** Adding **commercial-scale sterile injectables** capacity to increase output from 104 to 240+ batches annually. The upgrade will enhance efficiency and strengthen support for rising market demand.
- **Riverview:-** New commercial-scale suite for **payload-linker development and manufacturing**. This is in addition to our earlier investments totaling **US\$ 60 Mn in Riverview and Aurora** facilities towards significantly increasing our capacity for producing **APIs, HPAPIs, and payload-linkers**.

**Sellersville:-** Multi-million-dollar **joint investment** with NewAmsterdam Pharma to **provide commercial capacity** for fixed dose combination of Obicetrapib and Ezetimibe to meet commercial demand.

### Our Presence in the US

**3**

Manufacturing and  
Development Sites

**~US\$ 200 Mn**

Investment in US

**450+**

Employees

**HPAPI, Sterile Injectable,  
API, Formulation**

Capabilities

**USFDA, EMA, PMDA, HC**

Major Regulatory Accreditation

# Dedicated Suite to Enhance OSD Production at Sellersville, USA



**PPDS, India**

*Played crucial role in product development*



**Sellersville, USA**

*Dedicated OSD Suite*

**Pithampur, India**

*Dual Sourcing Support*



**Piramal**  
Pharma Solutions

*"We are thrilled to expand our OSD production capabilities at the Sellersville facility with this new manufacturing suite. This addition will not only enhance our production capacity and speed, but reinforce our commitment to patient centricity, too."*

*Peter DeYoung, CEO,  
Piramal Global Pharma*

The multi-million-dollar joint investment with NewAmsterdam Pharma will provide commercial capacity for fixed dose combination of Obicetrapib and Ezetimibe to meet commercial demand.



**NewAmsterdam**  
Pharma

*"By investing in PPS' Sellersville facility, we are enabling the manufacturing of the FDC with exceptional precision and efficiency to meet the future commercial demand. We are excited to continue growing alongside our trusted partner, PPS, and thrilled about the potential for our collaboration to benefit countless patients around the globe."*

*Douglas Kling, COO,  
NewAmsterdam Pharma*

# Complex Hospital Generics Business

## Performance Highlights

### ❖ Inhalation Anesthesia

- Continue to **consolidate our #1 position in the mature US Sevoflurane market**, with value share of 45% in Mar'25 - up from 44% in MAT Mar'24. (Source:- IQVIA)
- To drive growth, we are working on obtaining regulatory approvals for Sevoflurane in the ex-US markets from our Digwal plant in India.

### ❖ Intrathecal Therapy

- Continue to maintain our **#1 Rank** in intrathecal Baclofen segment in the US with **75%** value market share. (Source:- IQVIA)
- Intrathecal sales during the quarter was impacted due to temporary supply challenges. **Supplies expected to normalize in H2FY26.**


❖ **Injectable Pain Management** – Initiatives to resolve supply constraints starting to yield results.

### ❖ Differentiated and Specialty Products

- Continue to invest in 505(b)(2)'s, complex generics, differentiated generics, and branded products through in-licensing deals or co-development projects to enable long term growth.

## Revenue Growth

(In ₹ Crore)





## Performance Highlights


- ❖ **15%** Revenue growth in Q2 and H1 FY26 – **faster than market growth**.
- ❖ **Power Brands grew 20% YoY** during Q2FY26, contributing 51% to total PCH sales.
  - Growth was driven by Little's, Lacto Calamine, CIR, and i-range.
- ❖ **E-commerce sales** grew at over 40% YoY in Q2 and H1 FY26, contributing ~24% to PCH sales. Over 40% of e-commerce sales coming from quick commerce.
- ❖ **Advertisement spends in H1FY26 at 12%** of PCH sales.
- ❖ **Smooth transition to the changed GST rates** with no business impact.
- ❖ **New product launches** - 26 new products and SKUs launched in H1FY26. Products launched in last 24 months contributed 8% to PCH sales in FY25.



Lacto Calamine




Little's




i-range

## Revenue Growth


(In ₹ Crore)




# Focus on Power Brands with Brand Promotion and Marketing



## Investments in Brand Promotion and Marketing (In ₹ Cr)



## Strong Growth in our Power Brands (In ₹ Cr)



# Joint Venture with AbbVie

AbbVie Therapeutics India Private Limited, a joint venture between AbbVie and PPL, is one of the market leaders in the ophthalmology therapy area in the Indian pharma market



Ownership  
**49%**



**abbvie**

Ownership  
**51%**

In FY2025, the JV reported revenue of ₹494 Cr. with PAT margin of 28%

Brand ▶

Segment ▶



**Lumigan**

**Glaucoma**



**Combigan**

**Glaucoma**



**Refresh Tears**

**Dry Eyes**



**Alphagan**

**Glaucoma**



**Pred Forte**

**Eye Inflammation**





# Financials

---

# Consolidated Financials Highlights

(in ₹ Cr. or as stated)

Particulars	Q2FY26	Q2FY25	YoY Change	Q1FY26	QoQ Change	H1FY26	H1FY25	YoY Change
<b>Revenue from Operations<sup>1</sup></b>	<b>2,044</b>	<b>2,242</b>	<b>(9)%</b>	<b>1,934</b>	<b>6%</b>	<b>3,977</b>	<b>4,193</b>	<b>(5)%</b>
CDMO	1,044	1,324	(21)%	997	5%	2,041	2,381	(14)%
CHG	644	643	0%	637	1%	1,281	1,274	1%
ICH	319	277	15%	302	6%	621	541	15%
<b>EBITDA</b>	<b>224</b>	<b>403</b>	<b>(44)%</b>	<b>165</b>	<b>36%</b>	<b>389</b>	<b>627</b>	<b>(38)%</b>
<b>EBITDA Margin</b>	<b>11%</b>	<b>18%</b>		<b>9%</b>		<b>10%</b>	<b>15%</b>	
Share of Net Profit of Associates	15	17	(14)%	19	(20)%	33	40	(16)%
<b>PAT</b>	<b>(99)</b>	<b>23</b>	<b>NM</b>	<b>(82)</b>	<b>NM</b>	<b>(181)</b>	<b>(66)</b>	<b>NM</b>
<b>PAT Margin</b>	<b>(5)%</b>	<b>1%</b>		<b>(4)%</b>		<b>(5)%</b>	<b>(2)%</b>	

1. Revenue from Operations includes foreign exchange gains/losses

# Consolidated Financials Highlights

(in ₹ Cr. or as stated)

Key Balance Sheet Items	As on 30-Sep-25	As on 31-Mar-25
<b>Total Equity</b>	<b>8,073</b>	<b>8,125</b>
Net Debt	3,971	4,199
<b>Total</b>	<b>12,045</b>	<b>12,324</b>
<b>Net Fixed Assets</b>	<b>9,394</b>	<b>9,110</b>
Tangible Assets	4,655	4,534
Intangible Assets including goodwill	3,651	3,599
CWIP (including IAUD*)	1,088	977
Net Working Capital	2,201	2,798
Other Assets <sup>#</sup>	450	416
<b>Total</b>	<b>12,045</b>	<b>12,324</b>

\*IAUD – Intangible Assets Under Development

# Other Assets include Investments and Deferred Tax Assets (Net)





# Sustainability

---

# Innovating Responsibly. Growing Sustainably.




## Sustainability Purpose

Operating Responsibly.  
Growing Sustainably.



## Sustainability Vision

To become a globally leading integrated pharmaceutical company, operating on the principles of sustainability, inclusivity, and ethics.



The report has been assured by DNV Business Assurance India Pvt Ltd.

**Access the  
full report**

Piramal Pharma  
Sustainability  
Report FY 2025

**Scan Me**  
to view report



[Click here to access the full report](#)

# Embedding Sustainability in Every Step of Our Growth



## Responsible Operations

**Zero**

Hazardous Waste to Landfill

**2.10 Lakh**

Kiloliters of Freshwater  
Saved

**10.5%**

Reduction in Scope 1 & 2  
Emissions Over Base Year  
(FY22)

**14.08%**

Total Energy Sourced from Bio-  
Briquettes/Biomass



## Business Resilience

**50%**

Independent Directors  
on the Board

**100%**

Workforce Trained on Code of  
Conduct

**26.5%**

Of critical Suppliers Assessed  
on ESG

**Zero**

Cases of Data Breaches/  
Corruption Incidents



## Quality and Excellence

**36**

Successful Regulatory  
Inspections

**165**

Successful Customer Audits

**2**

Successful USFDA  
Inspections

**17**

KPI Dashboards to Digitalise  
Governance



## Stakeholder Centricity

**20%**

Of the Global Workforce are  
Women

**65/100**

EcoVadis Score  
(Bronze Medal)

**Zero**

Fatalities in the Last Four  
Years

**0.05**

Loss Time Injury Rate

# Dial-in Details for Q2 and H1 FY26 Earnings Conference Call

Event	Location & Time	Telephone Number
Conference call on 6 <sup>th</sup> November 2025	India – 09:30 AM IST	+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)
		1 800 120 1221 (Toll free number)
	USA – 11:00 PM (Eastern Time – New York)	Toll free number 18667462133
	UK – 04:00 AM (London Time)	Toll free number 08081011573
	Singapore – 12:00 PM (Singapore Time)	Toll free number 8001012045
	Hong Kong – 12:00 PM (Hong Kong Time)	Toll free number 800964448
Express Join with Diamond Pass™	Please use this link for prior registration to reduce wait time at the time of joining the call – <a href="#">Click here</a>	

## For Investor Queries:

### **Gagan Borana**

**Investor Relations and Enterprise Risk Management**

Email: [gagan.borana@piramal.com](mailto:gagan.borana@piramal.com)



### **Madhusudan Dalmia**

**Investor Relations**

Email: [madhusudan.dalmia@piramal.com](mailto:madhusudan.dalmia@piramal.com)



## Our Websites:-

### **Piramal Pharma Limited**

[www.piramalpharma.com](http://www.piramalpharma.com)

### **Complex Hospital Generics**

[www.piramalcriticalcare.com](http://www.piramalcriticalcare.com)

### **CDMO**

[www.piramalpharmasolutions.com](http://www.piramalpharmasolutions.com)

### **Piramal Consumer Healthcare**

[www.wellify.in](http://www.wellify.in)